reply to post by Hx3_1963
Glaxo to get initial vaccine production "rights"- and freely admit they must use an adjuvant to boost immunity (adjuvants are notorious for causing
or contributing to autoimmune diseases, Guillan Barre, etc.), and Glaxo has admitted that they are making the vaccine based on viral seed stock that
they have NOW, with the concern that by autumn, if the virus mutates, which it should do, it may be only partially effective, if at all.
Others (Sanofi, Novartis, etc.), are also in "the running" and each company stands to make billions- for a vaccine that may not work, and that is
filled with adjuvants that could cause worse illness.
Even Baxter, with it's history of error, is "in contention" for vaccine production.
this link may be more accessible:
and from the LA Times:
[edit on 19-5-2009 by CultureD]